Silo Pharma Takes Next Step in Bringing Homing Peptide Tech to $30+ Billion RA Market

CANNANNEW REPORT

Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease that causes painful swelling in joints in the hands, wrists, and knees. While medications can slow the disease and prevent joint deformity, there is no cure for the condition, and many millions still suffer from it. Silo Pharma Inc. (OTCQB: SILO) is a development-stage biopharmaceutical company leveraging homing peptides to improve cellular targeting. In RA, the company hopes to deliver dexamethasone via peptide-guided liposomes to enhance its efficacy and toxicity profile. Let’s take a look at the company’s recent move toward commercialization, as well as how its underlying technology could pave the way for expansion into other markets. Moving Toward Commercialization Silo Pharma extended its exclusive option agreement with the University of Maryland-Baltimore earlier this month to explore a novel intervention, generally known as “joint-homing peptides for use in the investigation and treatment of arthritogenic processes,” which has shown a lot of promise in early-stage research in targeting specific cells. The company subsequently entered into a Scientific Research Agreement with the university to evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via its peptide-guided liposomes. By selecting an FDA-approved drug, the researchers can focus on delivering the maximum possible dose to specific areas. Click here to receive investor information and corporate updates “This agreement is a milestone for the company as we add a significant addressable market for our therapeutic approach,” said Chairman and CEO Eric Weisblum in a press release. “This study will … help establish our hypothesis that we can not only target parts of the body but can lower toxicity and help keep healthy organs unexposed to therapeutics.” Expansion into Psychedelics Silo Pharma believes that the same peptide-guided liposomes are adaptable to other drugs because liposomes can be loaded with both hydrophobic and hydrophilic drugs, permitting…

Excerpt only …
READ MORE BELOW
Source : Silo Pharma Takes Next Step in Bringing Homing Peptide Tech to + Billion RA Market

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.